

FSL-1

Cat. No.:	HY-P2036
CAS No.:	322455-70-9
Molecular Formula:	C ₈₄ H ₁₄₀ N ₁₄ O ₁₈ S
Molecular Weight:	1666.16
Sequence Shortening:	S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF
Target:	Toll-like Receptor (TLR); Antibiotic
Pathway:	Immunology/Inflammation; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection ^{[1][2]} .									
IC₅₀ & Target	TLR2	TLR6								
In Vitro	<p>FSL-1 significantly reduces HSV-2 replication in vitro. FSL-1 reduces HSV-2 replication in human vaginal epithelial cells (EC)^[1].</p> <p>FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile^[1].</p> <p>FSL-1 enhances phagocytosis of bacteria by macrophages through a Toll-like receptor 2-mediated signalling pathway^{[1][2]}. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>V11I, V12I or V19I immortalized human vaginal EC</td> </tr> <tr> <td>Concentration:</td> <td>6 µg or 0.1 µg</td> </tr> <tr> <td>Incubation Time:</td> <td>Added at 24, 6 or just prior to HSV-2 inoculation (10⁴pfu/well)</td> </tr> <tr> <td>Result:</td> <td>The 6 µg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 µg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.</td> </tr> </table>		Cell Line:	V11I, V12I or V19I immortalized human vaginal EC	Concentration:	6 µg or 0.1 µg	Incubation Time:	Added at 24, 6 or just prior to HSV-2 inoculation (10 ⁴ pfu/well)	Result:	The 6 µg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 µg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.
Cell Line:	V11I, V12I or V19I immortalized human vaginal EC									
Concentration:	6 µg or 0.1 µg									
Incubation Time:	Added at 24, 6 or just prior to HSV-2 inoculation (10 ⁴ pfu/well)									
Result:	The 6 µg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 µg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.									

CUSTOMER VALIDATION

- Food Res Int. 10 October 2022, 112029.
- Int J Med Sci. 2022 Feb.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Rasheed Ahmad, et al. FSL-1 induces MMP-9 production through TLR-2 and NF- κ B /AP-1 signaling pathways in monocytic THP-1 cells. Cell Physiol Biochem. 2014;34(3):929-42.
- [2]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA